Growth hormone treatment in pre-pubertal short Chinese children with chronic kidney disease prior to transplantation.

What Was Tested

This randomized controlled trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

The effect of recombinant human GH (rhGH) in Chinese children with chronic kidney disease (CKD) is unclear.

Who Took Part

By PubMed's age tags, the people studied were young children and children.

How the Study Was Run

The researchers set it up as a randomized, open-label and multicenter study.

Random assignment meant chance, not the researchers, decided who got Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and who got the comparison, which limits bias.

Nothing was hidden in this open-label Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study: the participants and staff both knew the treatment.

More than one site took part, so the participants came from several places.

This was a 52-week, multicenter, randomized, open-label, negative-controlled phase 3 study.

What Was Measured

The subject headings attached to it are East Asian People, Growth Disorders, Human Growth Hormone, Growth Hormone, Renal Insufficiency, Chronic, Insulin-Like Growth Factor I and Recombinant Proteins.

What This Means in Plain Language

The paper is a randomized, open-label and multicenter study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2023 (Pediatric research), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.